1. Japan Stocks

  2. •

    Process industries

  3. •

    Chemicals: major diversified
Nippon Fine Chemical Co., Ltd.

Nippon Fine Chemical Co., Ltd.

TTSE:4362
2,734.00
JPY
-7.00
(-0.26%)
45.02BMarket Cap
Oct 30Next Earn
Nippon Fine Chemical Co., Ltd.
TSE:4362
(Tokyo Stock Exchange)

Recent

price

2,734.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
JPY
1,028.92
1,050.18
991.38
1,032.81
1,089.1
1,089.22
1,059.17
1,162.16
1,182.63
1,223.19
1,284.78
1,409.52
1,575.03
1,475.25
1,585.29
1,544.44
- -
Revenue per Share
42.51
37.19
49.96
47.56
59.89
75.77
76.46
84.83
96.98
110.38
116.18
146.32
174.42
146.4
172.07
202.38
- -
Basic EPS, GAAP
2.89
48.92
-49.14
57.18
115.45
32.94
64.11
130.31
113.57
50.86
82.33
-22.84
-56.35
220.51
76.01
174.84
- -
Free Cash Flow per Basic Share
22
22
21
20
20
22.5
23
23
28.5
33.5
34
43.53
57.57
64.27
72
84.62
- -
Dividend per Share
984.93
1,004.9
1,059.06
1,123.18
1,219.51
1,264
1,354.12
1,504.66
1,562.03
1,589.65
1,773.54
1,851.85
1,984.59
2,074.07
2,140.58
2,369.46
2,140.58
Book Value per Share
968.9
988.06
1,042.71
1,107.49
1,203.9
1,251.43
1,341.88
1,490.03
1,549.1
1,576.03
1,760.5
1,838.83
1,961.72
2,039.47
2,111.42
2,342.95
2,111.42
Tangible Book Value per Share
24
24
24
24
24
24
24
24
24
24
24
24
23
23
22
22
23
Basic Weighted Avg Shares
24,438
24,942
23,545
24,529
25,865
25,868
25,154
27,599
28,085
29,047
30,510
33,449
36,838
33,532
35,664
33,796
- -
Sales/Revenue/Turnover
6.56
5.32
6.99
6.46
8.1
9.21
9.42
9.96
11.39
12.54
12.91
14.6
13.73
12.52
13.73
15.81
- -
Operating Margin (%)
745
818
995
1,122
1,018
1,004
1,028
976
1,107
1,206
1,065
1,070
951
1,437
1,376
1,564
- -
Depreciation Expense
1,010
883
1,187
1,130
1,422
1,799
1,816
2,015
2,303
2,621
2,759
3,472
4,080
3,328
3,871
4,429
- -
Net Income, GAAP
38.22
38.09
33.38
37.15
34.2
28.37
26.11
28.28
31.37
28.84
29.37
28.99
26.19
29.75
26.24
29.91
- -
Effective Tax Rate (%)
4.13
3.54
5.04
4.6
5.5
6.96
7.22
7.3
8.2
9.02
9.04
10.38
11.07
9.92
10.85
13.1
- -
Profit Margin (%)
10,939
10,401
10,682
12,279
14,384
15,160
16,383
17,945
19,285
20,217
21,624
22,613
21,975
22,593
24,797
22,821
24,797
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
800
- -
800
LT Debt
23,808
24,330
25,750
27,366
29,748
30,734
32,846
36,450
37,796
38,399
42,847
44,560
46,101
47,559
49,069
52,390
49,069
Total Equity
4.06
3.38
4.32
3.69
4.76
5.57
5.45
5.62
5.82
6.71
6.76
7.78
8.09
6.17
7.27
7.19
- -
Return on Invested Capital (%)
3.99
3.45
4.33
4.05
4.78
5.76
5.48
5.64
6.03
6.65
6.59
7.74
8.81
6.91
7.73
8.49
- -
Return on Capital (%)
4.33
3.74
4.84
4.36
5.11
6.1
5.84
5.93
6.32
7
6.91
8.09
9.17
7.24
8.17
8.9
- -
Return on Common Equity (%)

Capital Structure

JPY

•

in mil. unless spec.
Jun'25
Sep'25
Mar'25
ST Debt
- -
- -
300
LT Borrowings
- -
- -
800
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
22
22
22
Market Capitalization
62,254
51,861
45,020

Working Capital

JPY

•

in mil. unless spec.
Jun'25
Sep'25
Mar'25
Total Current Assets
- -
30,375
32,214
Cash, Cash Equivalents & STI
- -
11,687
14,300
Accounts Receivable, Net
- -
8,598
8,221
Inventories
- -
9,608
9,253
Total Current Liabilities
- -
7,232
7,417
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
300
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.53%
4.11%
6.77%
Free Cash Flow
-21.53%
-81.4%
123.74%
Net Income, GAAP
10.09%
11.13%
14.41%
Sales/Revenue/Turnover
2.91%
2.38%
-5.24%
Total Cash Common Dividend
- -
18.4%
14.33%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
35,664
2026
- -
- -
- -
- -
33,796
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
172.07
2026
- -
- -
- -
- -
202.38
2027
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
72
2026
- -
- -
- -
- -
84.62
2027
- -
- -
- -
- -
- -
Similar Companies
Hektas Ticaret T.A.S. (BIST:HEKTS)
AARTI Industries Ltd (NSE:AARTIIND)
Aether Industries Ltd. (NSE:AETHER)
Mitsui & Co.,Ltd (TSE:8031)
Saudi Basic Industries Corp. (TADAWUL:2010)
Raghav Productivity Enhancers Ltd. (NSE:RPEL)
Business
Nippon Fine Chemical Co., Ltd. manufactures and sells fine chemicals, cosmetic ingredients, industrial chemicals, and related products primarily in Japan and internationally through its subsidiaries. Founded in 1918 as Nippon Camphor Co., Ltd. and renamed in 1971, the company is headquartered in Osaka, Japan, with key facilities including the Takasago Plant, Kakogawa-higashi Plant, Tokyo Office, and overseas subsidiaries such as Sichuan Nipo Fine Chemical Co., Ltd. in China and Zillion Fine Chemicals International Co., Ltd. in Taiwan; it operates in the Industrial Products and Household Products segments, targeting pharmaceutical, cosmetics, hygiene, electronics, and high-performance materials markets. Core products and services encompass high-purity phospholipids and liposomes for pharmaceuticals and cosmetics including Presome approved by FDA and EMEA; cosmetic ingredients such as functional esters, 100% plant-derived paste esters, active ingredients, and lipid complexes for skin care, makeup, and hair care; lanolin and cholesterol derived from sustainable wool sources used in pharmaceuticals, cosmetics, industrial applications, and feed additives; industrial chemicals including pharmaceutical ingredients, electronic materials, high-performance resins, fatty acid mono-amides, functional oils, and plastic coating agents; hygiene products for sanitation; contract manufacturing services as a CMO/CDMO with regulatory support, quality control, and custom phospholipid production; and real estate rental operations. Recent developments include the establishment of a new pharmaceutical phospholipids plant and a dedicated facility for Gilead Sciences at Takasago Plant in 2022; suspension of Kobe Factory operations in 2022; opening of Shonan Lab in Shonan Health Innovation Park and implementation of ISO 9001 management for non-GMP products in 2023; launch of the Open Lab (Design & Creation Lab.) at the head office in 2024; and construction of the new KSC office building at Kakogawa-higashi Plant in 2025.